Key Takeaways
What Is the Best Drug for Depression and Anxiety? No Single Winner
There is no single best drug for depression and anxiety. The closest the evidence comes is a short list of antidepressants that perform well in both bodies of research: escitalopram, an SSRI, and duloxetine and venlafaxine, both SNRIs, were more effective than placebo with relatively good acceptability in a 2019 Lancet network meta-analysis of 89 generalized anxiety disorder trials[1].
The depression evidence points in a similar direction. A 2018 Lancet review of 522 trials found that all 21 antidepressants studied beat placebo for adults with major depressive disorder, and escitalopram was among the drugs that ranked as both more effective and more tolerable in head-to-head trials[2].
The question matters because the two conditions usually travel together. In the National Comorbidity Survey Replication, 59.2% of adults with lifetime major depression also met criteria for an anxiety disorder[3]. How many people live with each condition is covered on the depression statistics page and the generalized anxiety disorder page.
What counts as best also varies. Trials rank drugs on efficacy (how much symptoms improve) and on acceptability (how many people stop taking the drug), and the leaders on one measure are not always the leaders on the other[2][1].
U.S. adults with lifetime major depression who also met criteria for an anxiety disorder
Because most people with major depression have also had an anxiety disorder, a drug's record across both conditions matters. The figure comes from the National Comorbidity Survey Replication, a face-to-face survey of 9,090 adults conducted in 2001 and 2002.
"including 59.2% with anxiety disorder"
Which Drugs Rank Well for Both Depression and Anxiety?
Putting the two largest network meta-analyses side by side shows where the evidence overlaps. In the depression review, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine and vortioxetine were more effective than other antidepressants in head-to-head trials. Agomelatine, citalopram, escitalopram, fluoxetine, sertraline and vortioxetine were more tolerable[2].
In the generalized anxiety disorder review, duloxetine improved HAM-A scores by 3.13 points more than placebo, pregabalin by 2.79, venlafaxine by 2.69 and escitalopram by 2.45, all with relatively good acceptability[1]. Mirtazapine, sertraline, fluoxetine, buspirone and agomelatine also looked effective and well tolerated, but those results rested on small samples[1].
Escitalopram and agomelatine are the only drugs on the favorable side of all three lists: more effective and more tolerable for depression, and effective and well tolerated for anxiety. The agomelatine anxiety result rests on small samples[2][1].
Venlafaxine and duloxetine rank well for anxiety, but both were among the antidepressants with the highest dropout rates in the depression review[2]. Paroxetine shows a split of its own: more effective for depression in head-to-head trials, but poorly tolerated in generalized anxiety disorder trials[2][1].
Each review was limited to one diagnosis, major depressive disorder or generalized anxiety disorder[2][1]. Neither directly measures how a drug performs when both conditions are present; that evidence comes from the studies of anxious depression below.
How Common Medications Rank in the Depression and Anxiety Reviews
| Drug | Class | Depression review (2018) | GAD review (2019) |
|---|---|---|---|
| Escitalopram | SSRI | More effective, more tolerable | Effective, relatively good acceptability |
| Sertraline | SSRI | More tolerable | Effective, well tolerated (small samples) |
| Fluoxetine | SSRI | More tolerable, among least effective | Effective, well tolerated (small samples) |
| Paroxetine | SSRI | More effective | Effective, poorly tolerated |
| Duloxetine | SNRI | Among highest dropout rates | Effective, relatively good acceptability |
| Venlafaxine | SNRI | More effective, among highest dropout rates | Effective, relatively good acceptability |
| Mirtazapine | Atypical antidepressant | More effective | Effective, well tolerated (small samples) |
| Pregabalin | Not an antidepressant | Not included | Effective, relatively good acceptability |
| Quetiapine | Antipsychotic | Not included | Largest effect, poorly tolerated |
| Benzodiazepines | Not antidepressants | Not included | Effective, poorly tolerated |
Findings for adults with major depressive disorder (Cipriani et al., 522 trials) and generalized anxiety disorder (Slee et al., 89 trials), as reported in each review's summary[2][1].
1Depression column: rankings from head-to-head trials among the 21 antidepressants; every antidepressant in the review beat placebo[2].
2GAD column: comparisons with placebo on HAM-A change and on discontinuation for any cause[1].
Sources
- •Cipriani et al., The Lancet, 2018
- •Slee et al., The Lancet, 2019
Which Antidepressants Are FDA-Approved for Both Depression and Anxiety?
FDA approval reflects the conditions a manufacturer proved a drug treats in trials submitted to the agency. Escitalopram (Lexapro) is approved for major depressive disorder in adults and children 12 and older, and for generalized anxiety disorder in adults and children 7 and older[4].
Duloxetine (Cymbalta) is approved for major depressive disorder in adults and generalized anxiety disorder in adults and children 7 and older[5]. It also carries approvals for diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain[5].
Extended-release venlafaxine (Effexor XR) is approved in adults for major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder[6].
Approval lists are not the full picture of use. NIMH notes that SSRIs and SNRIs are also used to treat anxiety, and that for panic disorder or social anxiety disorder, providers typically start with SSRIs or other antidepressants because they have fewer side effects than other medications[9].
The escitalopram label carries a boxed warning: antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies, and all treated patients are to be monitored for worsening and suicidal thoughts[4]. Side effects and stopping are covered in more detail in anti-depression meds.
Anxious depression
Major depressive disorder with prominent anxiety symptoms. In the STAR*D trial, patients were classified as having anxious depression when their anxiety/somatization factor score on the 17-item Hamilton Depression Rating Scale was 7 or higher at baseline[7].
Related Terms
Source: Fava et al., American Journal of Psychiatry, 2008
Does Anxiety Change How Well Antidepressants Work?
On average, yes. In the first treatment step of the STAR*D trial, in which patients took citalopram, 53.2% had anxious depression[7].
Remission was less likely and took longer for that group: 22.2% versus 33.4% on the HAM-D, and 27.5% versus 38.9% on the self-rated QIDS-SR[7]. Patients with anxious depression also reported more frequent and more intense side effects, and they fared worse at the second step whether they switched drugs or added one[7].
The authors concluded that anxious depression is associated with poorer acute outcomes after antidepressant treatment[7]. The analysis was secondary and observational within the trial, so it shows an association, not a cause.
When depression does not improve after adequate trials of medication, it may be classed as treatment-resistant depression. How depression and anxiety overlap and are diagnosed together is covered in depression and anxiety.
Where Bupropion, Benzodiazepines and Buspirone Fit
Bupropion
Bupropion, a norepinephrine-dopamine reuptake inhibitor, is one of the unranked first-choice options for depression in the 2022 VA/DoD guideline[10]. For anxious depression specifically, a pooled analysis of 10 randomized trials found response rates of 65.4% with SSRIs versus 59.4% with bupropion on the HAM-D[11].
The authors described this as a modest advantage for SSRIs: nearly 17 patients would need to be treated with an SSRI rather than bupropion to gain one additional responder[11].
Benzodiazepines
Benzodiazepines reduce anxiety symptoms but are not antidepressants. NIMH describes them as useful for short-term anxiety and notes that taking them over long periods may lead to tolerance or dependence[9].
In 2020 the FDA required an updated boxed warning for the class covering abuse, misuse, addiction, physical dependence and withdrawal reactions[8]. An estimated 92 million benzodiazepine prescriptions were dispensed from U.S. outpatient pharmacies in 2019, led by alprazolam (38%), clonazepam (24%) and lorazepam (20%)[8].
Buspirone
Buspirone must be taken every day for 3 to 4 weeks to reach full effect and does not work on an as-needed basis, according to NIMH[9]. It was effective and well tolerated in the generalized anxiety disorder review, though based on small samples[1]. It is not among the initial depression medications listed by VA/DoD[10].
What Guidelines Say About Choosing a First Medication
The 2022 VA/DoD guideline for major depressive disorder suggests offering one of bupropion, mirtazapine, an SNRI, trazodone, vilazodone, vortioxetine or an SSRI as the initial medication, and states that the options are not rank ordered[10].
It suggests against tricyclic antidepressants, MAO inhibitors, nefazodone, ketamine and esketamine as a first choice, citing harms such as the low therapeutic index of tricyclics and MAO inhibitors. Both recommendations are graded weak[10].
After a partial or no response to an adequate first trial, the guideline lists switching to another antidepressant, switching to psychotherapy, adding psychotherapy, or adding a second-generation antipsychotic, again without ranking[10]. The anxiety review reached a parallel conclusion: failure of the first drug might not be a reason to abandon medication altogether[1].
Timing shapes how any drug is judged. Antidepressants usually take 4 to 8 weeks to work, and sleep, appetite, energy and concentration often improve before mood does[9].
Rankings for anxiety alone, by disorder, are covered in what is the best medicine for anxiety, and SSRI comparisons in SSRI for anxiety. Prescription trends are tracked in antidepressant usage statistics.
Frequently Asked Questions
Sources & References
- Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. Published 2019. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31793-8/fulltext [Link]
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. Published 2018. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext [Link]
- Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. Published 2003. Accessed October 2026. https://jamanetwork.com/journals/jama/fullarticle/196765 [Link]
- U.S. Food and Drug Administration. Lexapro (escitalopram) prescribing information. Published 2023. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s055,021365s039lbl.pdf [Link]
- U.S. Food and Drug Administration. Cymbalta (duloxetine delayed-release capsules) prescribing information. Published 2020. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021427s052lbl.pdf [Link]
- U.S. Food and Drug Administration. Effexor XR (venlafaxine extended-release) prescribing information. Published 2023. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf [Link]
- Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. American Journal of Psychiatry. Published 2008. Accessed October 2026. https://psychiatryonline.org/doi/10.1176/appi.ajp.2007.06111868 [Link]
- U.S. Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Published 2020. Accessed October 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class [Link]
- National Institute of Mental Health. Mental health medications. National Institutes of Health. Published 2023. Accessed October 2026. https://www.nimh.nih.gov/health/topics/mental-health-medications [Link]
- U.S. Department of Veterans Affairs, U.S. Department of Defense. VA/DoD clinical practice guideline for the management of major depressive disorder, version 4.0. U.S. Department of Veterans Affairs. Published 2022. Accessed October 2026. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf [Link]
- Fava M, Papakostas GI, Stahl SM, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Journal of Clinical Psychiatry. Published 2008. Accessed October 2026. https://doi.org/10.4088/jcp.v69n0812 [Link]